anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A pharmaceutical composition for treating inflammatory disease and immune disease, which contains a metal nanoparticle is provided to suppress the generation of nitrogen oxide and cytokine and inhibit the activation of COX-2. A pharmaceutical composition for treating inflammatory diseases and immune diseases comprises a metal nanoparticle as an active ingredient. The metal nanoparticle is selected from gold nanoparticle, silver nanoparticle, and gold shell nanoparticle. Anti-inflammatory mechanism depends on the concentration of metal nanoparticle. The inflammatory disease or immune disease is arthritis, sepsis, inflammatory skin disease or autoimmune disease. The composition is formulated with a drug selected among anti-histamine drug, anti-inflammatory drug, anti-cancer drug, and antibiotic.
We have shown that patients with severe asthma have heterogeneous regional ventilation defects and air trapping. Some of these defects are persistent, while others can be provoked with virus-induced exacerbations or bronchial challenge and recur in the same general areas on repeated challenge, suggesting localized airway dysfunction. In preliminary studies, inflammatory parameters tended to be more prominent in segments that showed ventilation defects on imaging. Therefore, we hypothesize that asthma exacerbations, in some patients, are associated with incomplete recovery and activation of airway inflammatory cells in a regional distribution. This leads to enhanced airway injury with airway dysfunction as reflected by ventilation defects and air trapping, and a more generalized increase in disease severity. To evaluate this hypothesis we propose the following specific aims: 1. To refine phenotyping of severe asthma using new variables from multiple domains in a large longitudinal patient cohort; and to determine the contribution of asthma exacerbations to disease progression. 2. To characterize regional obstructive patterns at baseline and their relationship to changes in pulmonary function; and to determine how incremental changes in regional airway dysfunction after asthma exacerbations may contribute to severe asthma. 3. To determine the contribution of established and novel biomarkers (YKL-40, vWF, \& P-selectin), in refining the severe asthma phenotypes and the role of inflammatory cells in causing airway injury following virus-induced asthma exacerbations with subsequent development of ventilation defects.
A method of producing a desired procolagen or derivative thereof in a system which co-expresses and assembles at least one further procollagen or derivative thereof. The gene(s) for expressing pro-.alpha. chains or derivatives thereof for assembly into the desired procollagen has or have been exogenously selected from natural pro-.alpha. chains or exogenously manipulated such as to express said pro-.alpha. chains or derivatives thereof with domains which have the activity of C-terminal propeptide domains but which will not co-assemble with the C-terminal propeptide of the pro-.alpha.  chains or derivatives thereof that assemble to form the said at least one further procollagen or derivative thereof.
Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
The invention relates to a natural plant Peristrophe roxburghiana concentrate paste, and a preparation method and an application thereof. The concentrate paste comprises 75-85% of Peristrophe roxburghiana, 8-12% of tea tree branches and leaves, 3-7% of camphor tree branches and leaves and 3-7% of persimmon tree branches and leaves. The preparation method comprises the following steps: processing raw materials, immersing the raw materials, internally mixing the raw materials, and mixing the raw materials. The invention also discloses the application of the concentrate paste. The preparation method has the advantages of full utilization of pure natural plant resources, abundant sources of the raw materials, simplicity and low cost. The concentrate paste prepared by adopting the biotransformation principle of a physical technology is green, safe and environmentally-friendly, can be used to prepare colored cooked glutinous rice as a food dye or can be used in the preparation of beautifying and painting skincare cosmetic base materials, and lays a foundation for developing traditional colored cooked glutinous rice and beautifying and skincare cosmetics.
OBJECTIVE: To create, validate, and apply an aerodigestive provider assessment survey.
METHODS: A survey assessing provider knowledge and current practice in the transition of patients with chronic aerodigestive disorders from pediatric to adult care was drafted by a multidisciplinary expert panel. Once agreement of the initial survey items was obtained, the survey was distributed to a national multidisciplinary panel of aerodigestive experts for review. Responses from the national panel were systematically quantified and a content validity index (CVI) was calculated. A final survey was developed and distributed to pediatric and adult aerodigestive providers.
RESULTS: From the initial 22 items presented to the national panel, 20 of the initial questions were included in the final instrument. Two additional questions were developed as a result of feedback from the expert panel. All items included in the survey had an Item Content Validity Index (I-CVI) of >0.85. The average Scale CVI in proportion to the average proportion of relevance (S-CVI/Ave) for the tool was 0.88. The average Scale CVI in proportion to universal agreement (S-CVI/UA) was 0.52. The survey was then administered to pediatric and adult specialty providers at our institution. Twenty-two providers completed the final survey.
CONCLUSION: The content validity index measurements from this newly developed survey suggest that it is a valid tool for assessing current knowledge and practice in care transitions among patients with complex aerodigestive needs. The survey developed in this project has been used to identify knowledge gaps and process issues that can be addressed to ease the transition of adolescents from pediatric specialty care into adult specialty care.
The invention relates to a hydrolysis resistant, high molecular weight polymer represented by formula (I), wherein R is alkylene having from 3 to 8 carbon atoms which is optionally substituted with lower alkyl; R1? and R2? are each hydrogen or methyl; wherein R7? and R8? are each alkylene having from 1 to 18 carbon atoms and are optionally substituted with alkyl; the sum of r and t is one or two; R4? and R5? are each independently lower alkyl; R6? is alkyl, aralkyl or alkaryl having from 1 to 8 carbon atoms or N-alkylene lactam having from 3 to 8 carbon atoms; X?- is an anion derived from the group of halogen, SO3?, SO4?, HSO4? and R6?SO4?; M is a copolymerizable vinyl monomer; n has a value of from 10 to 99 mole %; m has a value of from 1 to 90 mole %, p has a value of from 0 to 20 mole % and the sum of m + n + p is 100; q and q' have the same value which is 0 or 1; s is the reciprocal of the number of negative charges in X; and the total amount of monomer represented by subscript m can be from 1 % to 100 % quaternized. The invention also relates to a process for the preparation of the polymer containing low residual monomer and to uses of the polymer.
Half of the subjects (30) will be assigned to the experimental group. Received sublingual dust mite drops (trade name: Changdi, Zhejiang Wuwu Biotechnology Co., LTD.) for sublingual immunotherapy.
The present disclosure relates to methods of regenerating cartilage. In an embodiment, a method inc udes initiating a release of precursor cells, including bone marrow cells and progenitor cells, into a cartilage defect; and applying a population of exogenous cells to the cartilage defect. The exogenous cells, selected from a group including chondrocytes, synoviocytes, fat pad cells, chondroprogenitor cells, mesenchymal stem cells, and any combination thereof, induce the pre cursor cells to form cartilage tissue through a release of factors by the exogenous cells. The factors stimulate the precursor cells to form cartilage cells. The cartilage cells then form cartilage tissue. The factors are selected from a group including transforming growth factors, fibroblast growth factors, platelet-derived growth factors, insulin-like growth factors, epidermal growth factors, interleukins, and any combination thereof. Other methods of regenerating cartilage are also disclosed.
HIV-infected patients treated with antiretroviral therapy for prolonged periods of time may show decreased levels of HIV-specific immune responses. In these patients, a prime-boost vaccine strategy may induce both humoral and cell-mediated immunity. The hypothesis of this study is that the vaccine strategy selected will be both safe and immunogenic in the patient population being tested.

Patients continue antiretroviral medications throughout the course of this study. All patients receive intramuscular injections of ALVAC-HIV (vCP 1452) and recombinant soluble gp160 MN/LAI-2 on Days 0, 30, 90, and 180. Patients are monitored for safety 30 minutes after each immunization and by telephone contact within 72 hours of each vaccination. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
Extracellular vesicles (EVs) are nanovesicles containing bioactive molecules including proteins, nucleic acids and lipids that mediate intercellular and inter-organ communications, holding promise as potential therapeutics for multiple diseases. Adipose tissue (AT) serves as a dynamically distributed energy storage organ throughout the body, whose accumulation leads to obesity, a condition characterized by infiltration with abundant immune cells. Emerging evidence has illustrated that EVs secreted by AT are the novel class of adipokines that regulate the homeostasis between AT and peripheral organs. However, most of the studies focused on the investigations of EVs derived from adipocytes or adipose-derived stem cells (ADSCs), the summarization of functions in cellular and inter-organ crosstalk of EVs directly derived from adipose tissue (AT-EVs) are still limited. Here, we provide a systemic summary on the key components and functions of EVs derived from healthy adipose tissue, showing their significance on the tissue recovery and metabolic homeostasis regulation. Also, we discuss the harmful influences of EVs derived from obese adipose tissue on the distal organs. Furthermore, we elucidate the potential applications and constraints of EVs from healthy patients lipoaspirates as therapeutic agents, highlighting the potential of AT-EVs as a valuable biological material with broad prospects for future clinical use.
A heparinase formulation derived from F. heparinum which meets all requirements for a clinical reagent that can eliminate heparin interference of normal blood function has been developed. The heparinase, derived from F. heparinum, is free of a component that inhibits coagulation. It is stable under normal manufacturing, shipping and clinical storage conditions for a least one year. The heparinase is useful in vitro to eliminate the interference in hematological assays due to the presence of heparin. The heparinase is also useful for the in vivo neutralization of heparin during surgical procedures. Advantages of this preparation are that it achieves neutralization faster and more completely than previously available compositions and is stable for long periods of time.
OBJECTIVE: Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions primarily affecting the intestines. This study aims to identify the nature and frequency of oral symptoms and signs in patients with ulcerative colitis and to explore the connection between these complications and the activity of the disease.
METHODS: This descriptive-analytical study involved ulcerative colitis patients who visited the gastroenterology clinic at Shahid Sayad Shirazi Hospital in Gorgan, along with an equal number of healthy companions as a control group in 2019. A gastroenterology internist assessed the disease severity through clinical examination and a simple clinical disease activity index for colitis patients. The collected data were then analyzed statistically using SPSS version 19.
RESULTS: The average age of patients in the case group was 41.84 ± 11.66 years, while in the control group it was 40.43 ± 12.67 years. There was a significant correlation between difficulty swallowing, burning sensation in the mouth, vomiting, acidic taste, the presence of oral ulcers, and a coated tongue with the severity of disease activity (p < 0.05). However, no significant relationship was found between other variables and the severity of disease activity (p > 0.05).
CONCLUSION: The results of this study confirm that as the severity of ulcerative colitis increases, the occurrence of oral lesions also rises, particularly during severe disease activity. Among oral symptoms, dry mouth had the highest incidence, followed by bad breath and changes in taste. The most common oral lesions observed were a coated tongue, grooved tongue, and oral ulcers, respectively.
This is a prospective cohort study of dynamic contrast enhanced MRI (DCE-MRI), which includes diffusion weighted imaging (DWI-MRI) in participants with pancreatic adenocarcinoma who are undergoing surgical resection. Participants will have up to two MRI scans with and without intravenous contrast. The MRI will be performed using either an extracellular contrast agent or using a macromolecular contrast agent. These contrast agents are routinely used in body MRI and are on formulary at this institution. Quantitative parameters of volume transfer coefficient (Ktrans) and apparent diffusion coefficient (ADC) will be calculated from the MRI sequences and each parameter will be compared to histopathology measures of mean vascular density and grade of fibrosis, respectively. The influence of the contrast agent (extracellular and macromolecular) on agreement between imaging parameters and histopathology will be assessed and agreement in Ktrans as derived from a one compartment and a two-compartment model will be assessed. If a participant is unable to receive intravenous contrast due to renal dysfunction or refuses IV contrast, the non-contrast portion of the exam will be used for analysis. The purpose is to establish a standard protocol for future clinical trials of treatments that would use MRI parameters as quantitative markers of treatment effect.
Cigarette smoking is a leading cause of morbidity and mortality from lung cancer among adults in the US. Stress relief and smoking cessation is the best preventive strategy for reducing lung cancer risk and addressing racial disparities in outcomes. Despite this, racial differences are found among those that make quit attempts. Stress has been found to be related to smoking initiation, maintenance, and relapse. Yet, differences in stress responses have not been examined between African American and white smokers. Therefore, this study will examine racial differences in stress responses and smoking behaviors between African American and white male smokers
Single dose administration of PF-07976016 and placebo. Participants will receive up to 4 dose levels of PF-07976016 or matching placebo.
Intra-treatment PETs have only recently been studied in small pilot series. In rectal cancer, a prospective trial from MSKCC demonstrated that a PET-CT obtained in the second week of neoadjuvant chemoradiotherapy was able to discriminate sub-optimal responders with a sensitivity of 94% and an accuracy of 78%, though the most useful metric was a novel "visual response score" based on interpreting radiologists scoring rather than more established objective data available from PET, like SUV. A study from China in non-small cell lung cancer found that decreases in SUV and MTV on intra-treatment PET-CTs after 40Gy of chemoradiation therapy were significantly greater in patients responding to treatment by post-treatment RECIST criteria. For head and neck cancers, a Belgian study found that intra-treatment SUVmax at 47Gy was associated with significant differences in overall survival. Therefore, there is emerging evidence that an intra-treatment PET may also be of significant prognostic utility, at an early enough time point to potentially alter treatment accordingly.

All participants will be required to complete two research PET scans in addition to standard of care planning CT's for radiation therapy. For all subjects with cancer of the cervix and vulva an intra-treatment PET-CT will be obtained and used to develop a volume adaptive treatment plan for the remainder of the course. Subjects with esophageal and anal canal cancer will have an adapted plan if the treating radiation oncologist determines an adapted plan is clinically relevant.
PURPOSE: The present study aimed to evaluate the role of early and delayed surgery in congenital brain tumors and analyze the clinical outcomes of infantile brain tumors.
MATERIALS AND METHODS: We performed a retrospective cohort study on 69 infantile brain tumors at a single institution from January 2008 to June 2023. Outcomes were assessed as early mortality (within 30 days following surgery) to evaluate the risk of early surgery in congenital brain tumors. Outcomes of recurrence and overall survival were analyzed in infantile brain tumors.
RESULTS: Surgery-related early mortality appeared to occur in young and low-body-weight patients. Cut-off values of age and body weight were found to be 1.3 months and 5.2 kg to avoid early mortality. Three patients (3/10, 30%) showed early mortality in the early surgery group, and early mortality occurred in one patient (1/14, 7.14%) in the delayed surgery group, whose tumor was excessively enlarged. Younger age at diagnosis (< 3 months of age; hazard ratios [HR], 7.1; 95% confidence intervals [CI], 1.4 to 35.6; p=0.018) and leptomeningeal seeding (LMS; HR, 30.6; 95% CI, 3.7 to 253.1; p=0.002) were significant independent risk factors for high mortality in infantile brain tumors.
CONCLUSION: We suggest delaying surgery until the patient reaches 1.3 months of age and weighs over 5.2 kg with short-term imaging follow-up unless tumors grow rapidly in congenital brain tumors. Younger ages and the presence of LMS are independent risk factors for high mortality in infantile brain tumors.
Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
The invention discloses a winter beverage for preventing and treating cement skin disease. The winter beverage is characterized by comprising a No.1 composition, wherein the No.1 composition is prepared from the following components in parts by weight: 2000 parts of water, 40-60 parts of radices paeoniae alba, 10-12 parts of dried rehamnnia root, 5-6 parts of coptis chinensis, 8-10 parts of white atractylodes rhizome, 8-10 parts of radix ophiopogonis, 5-6 parts of lalang grass rhizome, 8-10 parts of elaeagnus angustifolia, 10-15 parts of codonopsis pilosula, 2 parts of inula flowers, 2 parts of flos pyrethri tatsienensis, 5 parts of shellac, 10-15 parts of corn, 5-8 parts of the root of straight ladybell, 10-12 parts of Chinese yam, 5-6 parts of the fruits of Chinese wolfberry, and 8-10 parts of lotus seeds. The above components are mixed and boiled, and the decoction is filtered to obtain the beverage. The winter beverage for preventing and treating cement skin disease has a definite effect in treating cement skin disease, and the healing effective rate is high. In addition, the winter beverage also can improve the symptoms of some patients. Moreover, with the form of the beverage for prevention and treatment, the winter beverage has good friendliness. The invention further discloses a preparation method of the beverage.
Preoperative assessment of all patients undergoing elective surgical procedures under general anaesthesia comprises history taking, clinical examination, laboratory testing (complete blood count, kidney function tests, liver function tests), electrocardiogram, and chest X-ray. The study protocol will be explained to the patients, and their consent will be obtained. The patients will be continuously monitored in the operating room for heart rate, blood pressure, and oxygen saturation (baseline values). Then a 20-gauge cannula will be inserted.

Patients will be randomly assigned into two groups: Group A will receive Dexmedetomidine infusion dose of 1 mcg/kg diluted to 100 ml normal saline infused over 10 minutes and Group B will receive Dexmedetomidine bolus dose of 0.3 mcg/kg diluted to 10 mL normal saline administered intravenously over 60 seconds. Then Patients will be induced with propofol till loss of verbal contact, followed by atracurium 0.5 mg/kg IV. After 3 minutes, tracheal intubation will be performed with an appropriate size of cuffed tracheal tube and connected to end tidal CO2 monitor. After confirmation of bilateral equal air entry, it is connected to mechanical ventilation using isoflurane 1.2% for maintaining anesthesia and keeping end tidal CO2 between 35-40 mmHg, Ringer's solution at a rate 5ml/kg/hour IV will be infused for fluid maintenance. If heart rate falls below 45 bpm, rescue dose (500 mcg) of atropine will be given. If MAP decreases below 50 mmHg, boluses of 10 mg ephedrine will be given, while escalation of MAP will be treated by boluses of 50 mg propofol.

At the end of surgery, the inhaled gas is off and the patient is reversed with neostigmine 0.05mg/kg and atropine 0.01mg/kg, then extubation is done. The two groups will be observed for changes in hemodynamic parameters i.e. heart rate (HR) and mean arterial blood pressure at preinduction period (baseline), after 1 min from dexmeditomedine taking, after induction, at intubation and 1,3,5 and 10 min after intubation. No intervention will be allowed during these 10 minutes and morphine at a dose 0.1mg/kg will be used as analgesia for surgery after 10 minutes.
FIELD: medicine. SUBSTANCE: method involves culturing B. Subtilis 3H production strain on nutrient medium stimulating spore formation. Biomass is separated from the nutrient medium and concentrated by applying microfiltration method. The concentrate is mixed with stabilizing agents and calcium gluconate is added in the amount of 1.0-10.0 % by mass to give the biomass the required physical properties. The biomass is dried by applying cassette lyophilization. When required, the finished biomass is mixed with sorbent in 1:1 dry residue proportion. The liquid is separated by filtering and immobilized biomass granules by drying in vacuum until residual humidity reaches 8-10%. After being dried, the biomass is mixed with auxiliary substances in 2: 1-3: 1 proportion and tablets are produced. Calcium stearate, talc and/or starch and/or Aerosil, glucose, dry milk and/or cellulose. EFFECT: manifestation of therapeutic properties in upper regions of the gastroenteric tract. 4 cl